Mumbai: Venus Remedies Limited, a pharmaceutical company specializing in critical care injectables, has announced that its ...

Recent discoveries are helping scientists face this challenge in innovative ways. Studies have found that nearly a quarter of drugs that aren’t normally prescribed as antibiotics, such as medications ...

The QIDP status, granted by USFDA makes VRP-034 eligible for regulatory benefits including priority FDA review, potential ...

The Venus Remedies investigational product, VRP-034, has been granted QIDP designation by the US FDA for the treatment of bloodstream infections caused by polymyxin B (PMB)-susceptible strains in adul ...

Venus Remedies’ novel polymyxin B formulation, VRP-034 gets US FDA QIDP designation: Our Bureau, Bengaluru Thursday, April 17, 2025, 12:15 Hrs [IST] Venus Remedies’ investigat ...

The human immune system is highly complex and well-equipped to combat most bacteria. However, in some instances bacteria can cause life-threatening infections and the increase of antibiotic-resistant ...

Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and ...

a pro-rata non-renounceable entitlement offer of one (1) New Share for every six (6) existing fully paid ordinary shares in the Company (Shares) held by eligible shareholders at the Offer Price to ...

Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company developing specialty therapies for community care and public health challenges, today announced that data from several new ...

Oral Presentation: Efficacy and safety in a Phase 2 study of intravenous BV100 combined with polymyxin B versus best available therapy in adult subjects with ventilator associated bacterial pneumonia ...

While Africa contributes about 30% of global births, around 70% of the 287 000 global maternal deaths annually occur on this ...